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A plethora of cellular and molecular signaling pathways
are elicited in response to vascular trauma that eventuates
in formation of an invasive neointima and adaptive
remodeling of the vessel wall. The pivotal role of nitric
oxide (NO) and downstream soluble guanylate cyclase
(sGC)/cyclic guanosine monophosphate (cGMP) in
mediating vasoprotection under both homeostatic and
inimical conditions has been extensively studied in clini-
cal medicine and basic science research. Recently, the par-
allel system of sGC-activating heme oxygenase (HO) and
the diatomic gas carbon monoxide (CO) has emerged as
a viable alternate pathway in mediating vascular protec-
tion following injury. Potential candidate factors involved
in this regulation include inducible HO (HO-1) and CO
and the novel exogenous sGC/cGMP-sensitizing agents
YC-1 and BAY 41-2272. The overall goal of these studies
is to elucidate potential protective influence of these NO-
independent systems in regulating the neointimal and
vascular remodeling responses to experimental carotid
artery balloon injury in laboratory rats. Results show that
HO-1 and CO independently attenuate neointima devel-
opment 2 weeks following injury through inhibition of
acute vascular smooth muscle cell (SMC) DNA synthesis
and proliferation, decreased acute expression of growth-
promoting TGF-β1 and the G1 cyclins E and A, and
enhanced SMC apoptosis. Similar experiments utilizing
the sGC-sensitizing benzyl indazole compound YC-1
found vessel wall cGMP to correlate with reduced vascular
SMC growth and platelet function and diminished
neointima formation. Promising early results suggest the
NO-independent sGC activator BAY 41-2272 reduces the
neointimal response to injury through anti-proliferative
and anti-migratory actions on vascular SMCs. In addition,
the anti-proliferative effects of BAY 41-2272 were signifi-
cantly potentiated in the presence of the HO-1 inducer
and substrate hemin. These cumulative results strongly
suggest that the HO-1/CO system and novel NO-inde-
pendent routes of sGC/cGMP activation exert salutary
influence upon compromised blood vessels via regulation
of various cellular growth-promoting functions and may
represent attractive therapeutic strategies aimed at reduc-
ing vascular lesion formation.
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